Repligen Corp (NAS:RGEN)
$ 169.685 -2.095 (-1.22%) Market Cap: 9.48 Bil Enterprise Value: 9.47 Bil PE Ratio: 678.74 PB Ratio: 4.81 GF Score: 93/100

Repligen Corp at KeyBanc Capital Markets Life Sciences & Medtech Investor Forum (virtual) Transcript

Mar 24, 2021 / 01:15PM GMT
Release Date Price: $189.05 (-8.49%)
Paul Richard Knight
KeyBanc Capital Markets Inc., Research Division - MD & Senior Analyst

Good morning. This is Paul Knight, the analyst at KeyBanc covering Repligen in the life science industry. Welcome to the Repligen fireside chat. We have Tony Hunt, CEO of Repligen; Jon Snodgres, the CFO; Sondra Newman of Investor Relations; and Steve Chehames in Investor Relations as well.

The format will be just a brief overview from Tony on the business, and then we'll -- I'll run some Q&A. But for people who are online, there's a section at the bottom of your screen where you may submit questions. I'll take those questions and ask management what you're asking.

And with that, Tony, I'll let you begin.

Anthony J. Hunt
Repligen Corporation - CEO, President & Director

Great. Thanks, Paul, and Jon and myself will tag team today. Yes, maybe the best way to kind of talk about where the company is, maybe highlight what's happened over the last year, we obviously had a great year in 2020, up 36%.

Half of our growth came from -- that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot